Is retatrutide available for prescribing to treat obesity or type 2 diabetes, and how can a patient access it?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Retatrutide Availability and Access

Retatrutide is NOT currently available for prescribing to treat obesity or type 2 diabetes, as it remains an investigational drug undergoing Phase 3 clinical trials. 1

Current Regulatory Status

Retatrutide is a novel triple receptor agonist (targeting GLP-1, GIP, and glucagon receptors) that is still in clinical development. While the drug has shown remarkable efficacy in Phase 2 trials, it has not yet received FDA approval for any indication 2, 3.

Clinical Trial Evidence

The available evidence comes exclusively from research trials:

  • Phase 2 trials demonstrated substantial weight loss of 17.5% at 24 weeks and 24.4% at 48 weeks in adults with obesity 4
  • TRIUMPH-2 trial (Phase 3, completed) showed weight reductions of 11.9% to 18.8% at 80 weeks in patients with obesity and type 2 diabetes 2
  • The drug achieved superior weight loss compared to currently approved GLP-1 receptor agonists 5

How Patients Can Access Retatrutide

Clinical Trial Enrollment

The ONLY way patients can currently access retatrutide is through enrollment in ongoing Phase 3 clinical trials:

  • Search ClinicalTrials.gov for active TRIUMPH studies (TRIUMPH-2 is completed; other TRIUMPH trials may be recruiting)
  • Contact Eli Lilly and Company directly about trial participation opportunities
  • Discuss with your physician whether you meet eligibility criteria for ongoing trials

Eligibility Criteria (Based on Completed Trials)

Typical inclusion criteria from TRIUMPH-2 included 2:

  • Adults ≥18 years old
  • BMI ≥27 kg/m² with type 2 diabetes (HbA1c 6.5-10.5%)
  • Stable diabetes treatment for ≥90 days
  • History of unsuccessful dietary weight loss attempts

Timeline for Availability

Phase 3 trials are currently underway, with the TRIUMPH-2 study completed in November 2024 2. However:

  • FDA review and approval typically takes 6-12 months after trial completion and submission
  • No official FDA approval date has been announced
  • The drug is NOT available through compassionate use or expanded access programs at this time

Currently Available Alternatives

While awaiting retatrutide approval, FDA-approved options with proven efficacy include 6:

For Obesity and Type 2 Diabetes:

  • Tirzepatide (Mounjaro for T2DM, Zepbound for obesity): Dual GIP/GLP-1 agonist achieving 15-20% weight loss 6
  • Semaglutide 2.4 mg (Wegovy): GLP-1 agonist achieving 12-17% weight loss 7, 8
  • Liraglutide 3.0 mg (Saxenda): GLP-1 agonist achieving 5-8% weight loss 9, 8

Key Distinction:

Tirzepatide is currently the most potent FDA-approved option and should be prioritized for patients with both obesity and type 2 diabetes, as it provides the closest approximation to retatrutide's mechanism (dual vs. triple agonism) 6.

Important Caveats

  • Do not delay treatment waiting for retatrutide approval—current therapies provide substantial benefits for morbidity and mortality
  • Patients interested in retatrutide should maintain treatment with approved medications while exploring trial enrollment
  • Insurance will not cover investigational drugs outside of clinical trials
  • Off-label use is not possible as the drug is not manufactured for commercial distribution

References

3
Research

Retatrutide in type 2 diabetes mellitus and obesity: an overview.

Expert review of clinical pharmacology, 2026

7
Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Related Questions

Does retatrutide have evidence of benefit on atherosclerosis in an adult with obesity without diabetes?
Does retatrutide reduce body weight and improve insulin resistance in patients with obesity and type 2 diabetes?
Can retatrutide be used to treat dementia or promote weight loss in an older adult with dementia and obesity?
What is the appropriate dosing regimen of retatrutide for weight loss in an adult patient with obesity (BMI ≥ 30 kg/m²) without contraindications?
Can you provide the dosing schedule, indications, contraindications, adverse effects, and monitoring recommendations for retatrutide in adult patients with obesity and type 2 diabetes?
What is the recommended management for refractory bacterial vaginosis?
What is the recommended nicotine transdermal patch dosing schedule for an adult smoker, including initial dose, step‑down regimen, and contraindications?
Why should long‑term back braces or abdominal binders be avoided in patients with chronic low back pain, and what is the appropriate management?
What is the recommended nicotine patch dosing schedule for adults based on smoking intensity, and what are the contraindications and alternative nicotine‑replacement or pharmacologic therapies?
What is my ASCVD (Atherosclerotic Cardiovascular Disease) risk score?
What starting dose of losartan should be used for a patient with systolic blood pressure in the 130 mmHg range?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.